American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Oct 2013
Randomized Controlled Trial Multicenter StudyComparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis.
Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking. ⋯ The choice of LFX or MXF for treatment of patients with MDR-TB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145).